C-Diff Toxin Testing and Treatment
Use a two-step diagnostic algorithm combining glutamate dehydrogenase (GDH) screening with toxin A/B detection, and treat initial non-severe infections with oral vancomycin or fidaxomicin—metronidazole is no longer recommended as first-line therapy. 1
Diagnostic Approach
When to Test
Test only patients with three or more episodes of unexplained, unformed stools in 24 hours who are not taking laxatives 2. Do not test asymptomatic patients or formed stools, as this leads to detecting colonization rather than active infection.
Two-Step Testing Algorithm
The optimal laboratory diagnosis uses a multi-step approach rather than a single test 1:
Step 1: Initial Screening
- Perform GDH enzyme immunoassay (highly sensitive, detects all C. difficile strains)
- GDH alone lacks specificity since it detects both toxigenic and non-toxigenic strains 1
Step 2: Confirmatory Testing
- If GDH positive → perform toxin A/B enzyme immunoassay
- Alternatively, use nucleic acid amplification testing (NAAT/PCR) for toxin genes 1, 2
Understanding Test Performance
The key challenge is that patients may harbor toxigenic strains without clinical disease 1. Here's how tests compare:
- Toxin EIAs: Low sensitivity but moderate specificity—detects free toxins (actual disease) 1
- NAAT/PCR: High sensitivity but low-to-moderate positive predictive value—detects toxin genes (potential for disease) 1
- Two-tier approach: Combining GDH + toxin testing improves accuracy and identifies active infection rather than colonization 3
Recent data shows toxin-positive patients have more colitis symptoms, higher white blood cell counts, and higher mortality compared to toxin-negative patients 3. Among PCR-positive patients, only 32% tested toxin-positive, and 44% of toxin-negative patients were appropriately not treated with antibiotics 3.
Critical Pitfall
If clinical suspicion remains high despite negative testing, consider colonoscopy to evaluate for pseudomembranous colitis 4. False negatives can occur, particularly with frozen samples which negatively affect both GDH and toxin detection 5.
Treatment Regimen
Initial Episode - Non-Severe Disease
- Oral vancomycin (125 mg four times daily for 10 days), OR
- Oral fidaxomicin (200 mg twice daily for 10 days)—preferred over vancomycin 6
Metronidazole is NOT adequate first-line treatment 6, 2
Severity Assessment
Classify based on:
- White blood cell count (>15,000 cells/μL suggests severe)
- Serum creatinine (>1.5 mg/dL suggests severe)
- Clinical signs: hypotension, shock, ileus, megacolon 2
Recurrent Infections
- Multiple recurrences: Fecal microbiota transplantation (FMT) after at least three episodes of appropriate antibiotic therapy 2
- High-risk patients: Consider bezlotoxumab (anti-toxin B antibody) to prevent recurrence 7
Severe Complicated Disease
Complications include pseudomembranous colitis and toxic megacolon requiring immediate intervention 7. Surgery is indicated for patients with poor prognosis and complications 6.
Clinical Judgment Required
Important caveat: Some toxin-negative patients still have colitis symptoms and respond to antibiotics 3. The two-tier strategy effectively improves antibiotic stewardship, but clinical judgment remains essential when test results are discrepant with clinical presentation 3, 4.